This is a modular Phase I/IIa, open-label, multi-centre, study of AZD7648 administered
orally, either as a monotherapy, or in combination with either cytotoxic chemotherapies or
novel anti-cancer agents in participants with advanced malignancies.
The modular design allows for an escalation of the dose of AZD7648 alone or in combination
with either cytotoxic chemotherapies or novel anti-cancer agents, with intensive safety
monitoring to ensure the safety of the participants.
The study consists of 2 modules each evaluating the safety and tolerability of AZD7648
monotherapy or with a specific combination partner.
Core module of the study is dose escalation (Part A) of AZD7648 monotherapy, administered
orally, in participants with advanced solid tumours.
Combination module 1 has 2 study parts: Part A consisting of dose escalation cohorts and Part
B, a safety and proof of concept Phase IIa expansion. A Safety Review Committee will review
evaluable participants at each cohort and assess if the study should progress to Part B.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.